Comparative Pharmacology
Head-to-head clinical analysis: ALBENDAZOLE versus PIPERAZINE CITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALBENDAZOLE versus PIPERAZINE CITRATE.
ALBENDAZOLE vs PIPERAZINE CITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Albendazole inhibits tubulin polymerization by binding to beta-tubulin, disrupting microtubule formation, which leads to impaired glucose uptake and depletion of glycogen stores in susceptible parasites, resulting in their immobilization and death.
Piperazine citrate acts as a gamma-aminobutyric acid (GABA) receptor agonist in nematodes, causing hyperpolarization of nerve membranes and flaccid paralysis of the worm, which is then expelled by normal peristalsis. It does not affect mammalian neuromuscular junctions due to differences in GABA receptor sensitivity.
400 mg orally twice daily for 3-7 days for most indications; for neurocysticercosis, 400 mg orally twice daily for 8-30 days; for hydatid disease, 400 mg orally twice daily for 28-day cycles with 14-day drug-free intervals for 3 cycles.
Adults: 3.5 g orally once daily for 2 days; may repeat after 1 week if needed.
None Documented
None Documented
Clinical Note
moderateAlbendazole + Digoxin
"Albendazole may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateAlbendazole + Digitoxin
"Albendazole may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateAlbendazole + Deslanoside
"Albendazole may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateAlbendazole + Acetyldigitoxin
"Albendazole may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life of albendazole sulfoxide is 8–12 hours; parent drug half-life is <1 hour. Clinical context: supports once- or twice-daily dosing.
Terminal elimination half-life: 2-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Primarily renal (80%) as inactive metabolites; <2% unchanged in urine. Biliary/fecal excretion accounts for ~20%.
Primarily renal (60-70% unchanged); biliary/fecal elimination accounts for 10-20% of the dose.
Category D/X
Category C
Anthelmintic
Anthelmintic